Dosage optimization of piperacillin/tazobactam in ICU patients based on therapeutic drug monitoring of amikacin - OPTIMA - OPTIMA

Hospices Civils de Lyon0 个研究点目标入组 60 人开始时间: 2018年11月6日最近更新: 2024年3月18日

适应症

试验速览

暂无简介。

•- Patient, male or female, over the age of 18, hospitalized in the critical care unit of the Lyon-Sud Hospital Center.
•- Patient presenting a clinical picture of sepsis or severe sepsis defined by the latest international recommendations.
•- Patient to be treated with amikacin + piperacillin / tazobactam.
•- Patient affiliated to a social security scheme,
•- having agreed to participate in the study
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 40
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

•- Minor patient.
•- Patient participating in another research potentially interfering (investigator's judgment) with the results of this study.
•- Refusal of the patient to participate in the study.
•- Major patient protected under the terms of the law (Public Health Code).
•- Patient with a known history of hypersensitivity or contraindication to amikacin, piperacillin or tazobactam.
•- Patient known to have previously received piperacillin / tazobactam or amikacin prior to inclusion of the patient.
•- Patient treated at the time of inclusion by extra-renal cleansing techniques.

发起方